TYK-00540
Phase 2Small molecule
TYK-00540 is one of 112 small molecule programs targeting Patients With Solid Tumors. It is currently in Phase 2.
3
Indications
3
Total Trials
3
Active Trials
111
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Paraplatin
AAvyxa
Phase 3
Tecentriq
RochePhase 3
Alinamin
RochePhase 3
Orgovyx
Sumitomo Pharma America, Inc.Phase 3
Ritalin
NovartisPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
TYK-00540
TTYK Medicines, Inc
Phase 2
Trexall
Jazz PharmaceuticalsPreclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer1 trial
Patients With Advanced Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TYK-00540. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTYK Medicines, Inc